8-K current report · filed Nov 5, 2026

PUMA BIOTECHNOLOGY, INC. (PBYI) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1PBYI overview

Short answer

PUMA BIOTECHNOLOGY, INC. (PBYI) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for the quarter ended September 30, 2026 announced.

PUMA BIOTECHNOLOGY, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026 announced
  • Full financial results and management commentary provided in Exhibit 99.1
  • Investor focus: revenue, profitability, cash position, and Nerlynx performance in the accompanying release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 product revenue $54.1M, up from $51.9M, signaling higher NERLYNX demand despite gross-to-net pressure
  • Q3 net income $6.0M versus $8.8M, while R&D increased to $18.3M to support alisertib trials
  • Cash, equivalents and marketable securities $108.5M, up from $97.5M, with current debt reduced to $0
  • 2026 net income guidance raised to $20M-$22M from $17M-$20M
  • Alisertib pipeline advancing with ALISCA-Lung2 initiated and Phase III regulatory discussions targeted for H1 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PUMA BIOTECHNOLOGY, INC. 8-K filings

Get the next PBYI 8-K as it lands

Follow PBYI for push alerts, or ask the research agent what this filing means.